Cargando…

Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment

BACKGROUND: Sorafenib is the current standard of care for patients with advanced hepatocellular carcinoma (aHCC) and has been shown to improve survival by about 3 months compared to placebo. However, survival varies widely from under three months to over two years. The aim of this study was to build...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berhane, Sarah, Fox, Richard, García-Fiñana, Marta, Cucchetti, Alessandro, Johnson, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738086/ https://www.ncbi.nlm.nih.gov/pubmed/31182766 http://dx.doi.org/10.1038/s41416-019-0488-4

Ejemplares similares

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma
por: Ho, Chun-Ming, et al.
Publicado: (2022)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach
por: Han, Guohong, et al.
Publicado: (2020)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

JOCR: Personalised Journal, Personalised Network and Clinical Decision Making (CDM)
por: Shyam, Ashok
Publicado: (2012)

Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
por: Lué, Alberto, et al.
Publicado: (2017)

Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib
por: Meng, Xiao-Chun, et al.
Publicado: (2018)

Using deep learning–derived image features in radiologic time series to make personalised predictions: proof of concept in colonic transit data
por: Kelly, Brendan S., et al.
Publicado: (2023)

Predictive diagnostics and personalised medicine in paediatrics
Publicado: (2011)

Education in predictive, preventive and personalised medicine
Publicado: (2011)

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2019)

Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Lee, Sangheun, et al.
Publicado: (2015)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
por: Wang, Wen-Quan, et al.
Publicado: (2014)

Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib
por: Zhong, Bin-Yan, et al.
Publicado: (2021)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Imai, Kenji, et al.
Publicado: (2015)

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Zheng, Liming, et al.
Publicado: (2021)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting
por: Hagenmaier, H. S. Femke, et al.
Publicado: (2021)

Machine learning application in personalised lung cancer recurrence and survivability prediction
por: Yang, Yang, et al.
Publicado: (2022)

General Report & Recommendations in Predictive, Preventive and Personalised Medicine 2012: White Paper of the European Association for Predictive, Preventive and Personalised Medicine
por: Golubnitschaja, Olga, et al.
Publicado: (2012)

Personalising cancer medicine with prognostic markers
por: Kerr, David J, et al.
Publicado: (2021)

Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib
por: Lee, Shou‐Wu, et al.
Publicado: (2018)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

Rapid Depletion of Subcutaneous Adipose Tissue during Sorafenib Treatment Predicts Poor Survival in Patients with Hepatocellular Carcinoma
por: Imai, Kenji, et al.
Publicado: (2020)

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma
por: Zhu, Zhenfeng, et al.
Publicado: (2018)

PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma
por: Wang, Pusen, et al.
Publicado: (2020)

Modelling Circulating Tumour Cells for Personalised Survival Prediction in Metastatic Breast Cancer
por: Ascolani, Gianluca, et al.
Publicado: (2015)

Digital Health in Focus of Predictive, Preventive and Personalised Medicine
por: Mszar, Reed
Publicado: (2021)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma
por: Liang, Yuelong, et al.
Publicado: (2017)

Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma
por: Yuan, Wei, et al.
Publicado: (2021)

Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib
por: Hsieh, Ming-Han, et al.
Publicado: (2020)

Gene signature to predict prognostic survival of hepatocellular carcinoma
por: Li, Li, et al.
Publicado: (2022)

Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam
por: Nguyen, Thi Thu Huong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vn98fph7r3qsoj7ch54hrqi10b